18 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. 10 Phase 1, 4 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 8, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Completed 3, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Parasitemia: new trials by email Literature Review of Parasitemia trials Research Report on Parasitemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 220 | 2026-11-17 | 2026-11-12 |
| Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays P. vivax challenge agent derived from PvHMB-CCE001 - Malaria | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 300 | 2024-11-26 | 2026-11-10 |
| Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum MMV367 3mg, P. falciparum IBSM infection, MMV367 5mg - Infections, Vector Borne Diseases | Phase 1 | Completed | Medicines for Malaria Venture | 12 | 2023-08-01 | 2025-12-10 |
| Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria Pyronaridine, P. falciparum IBSM infection - Malaria,Falciparum, Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 10 | 2022-04-04 | 2025-04-16 |
| Blood-Stage Plasmodium Vivax Cell Bank HMPBS02-Pv - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2 | 2022-02-15 | 2023-07-11 |
| Molecular Basis of Erythrocyte Invasion by Plasmodium Vivax Into Duffy-Negative Erythrocytes in Mali Malaria | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 667 | 2021-06-30 | 2023-10-31 | |
| Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet, PfSPZ-DVI Challenge - Malaria,Falciparum, Parasitemia | Phase 1 | Completed | Medicines for Malaria Venture | 16 | 2020-02-19 | 2021-09-05 |
| Trial to Evaluate CIS43LS in Healthy Adults VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 71 | 2020-01-07 | 2023-04-18 |
| Plasmodium and Other Parasites in Pregnant Women and Children Around Margibi and Montserrado Counties, Liberia Malaria | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1264 | 2019-10-01 | 2026-03-18 | |
| Aggressive Antipyretics for Fever Reduction in CNS Malaria Acetaminophen, Ibuprofen, placebo for acetaminophen - Malaria, Seizures | Phase 2 | Completed | University of Rochester | 256 | 2019-01-07 | 2024-03-05 |
| Dose Escalation PfSPZ-CVac Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 55 | 2017-06-05 | 2021-06-01 |
| Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania sulfadoxine-pyrimethamine (SP), dihydroartemisinin-piperaquine (DHA-PQP) - Malaria, Pregnancy Malaria | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 201 | 2016-09-01 | 2021-02-02 |
| Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Doneguebougou, Mali Malaria | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 290 | 2016-01-15 | 2018-06-14 | |
| Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults Malaria | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 49 | 2015-09-04 | 2019-12-17 | |
| Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children Malaria | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2015-07-21 | 2018-06-14 | |
| Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda Malaria | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 173 | 2014-03-07 | 2018-04-05 | |
| Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults PfSPZ Vaccine - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 141 | 2013-12-12 | 2019-12-17 |
| A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection KAE609 - Cure Rate | Phase 2 | Completed | Novartis Pharmaceuticals | 11 | 2013-07-01 | 2015-09-10 |
| Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax, Chloroquine and Primaquine - Parasitemia | Unknown | Ministry of Health, Bhutan | 50 | 2013-03-01 | 2013-11-25 | |
| Experimental PfSPZ Vaccine in Adults Without Malaria PfSPZ - Malaria, Prevention and Control | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 64 | 2011-09-14 | 2018-07-05 |
Showing 20 of 21. Sign in to see all of them.
Malaria (18) · Malaria, Falciparum (4) · Protozoan Infections (4) · Infections (3) · Parasitic Diseases (3) · Anemia (1) · Cardiotoxicity (1) · Coma (1) · Fever (1) · Hyperthermia (1) · Inflammation (1) · Malaria, Vivax (1) · Pathologic Processes (1) · Seizures (1)
Pathological Conditions, Signs and Symptoms (21) · Sepsis (21) · Inflammation (20) · Pathologic Processes (20) · Systemic Inflammatory Response Syndrome (20) · Infections (18) · Mosquito-Borne Diseases (18) · Parasitic Diseases (18) · Vector Borne Diseases (17) · Protozoan Infections (15) · Wounds and Injuries (2) · Body Temperature Changes (1) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Consciousness Disorders (1)
Acetaminophen (1) · Artemether, Lumefantrine Drug Combination (1) · CIS43LS (1) · Chloroquine (1) · Ibuprofen (1) · NITD 609 (1) · Primaquine (1) · Pyrimethamine (1) · chloroquine diphosphate (1) · fanasil, pyrimethamine drug combination (1) · pyronaridine (1)
National Institute of Allergy and Infectious Diseases (NIAID) (13) · Medicines for Malaria Venture (3) · London School of Hygiene and Tropical Medicine (1) · Ministry of Health, Bhutan (1) · Novartis Pharmaceuticals (1) · UPECLIN HC FM Botucatu Unesp (1) · University of Rochester (1)
United States (7) · Mali (4) · Australia (2) · Belgium (1) · Bhutan (1) · Brazil (1) · Liberia (1) · Malawi (1) · Tanzania (1) · Thailand (1) · Uganda (1) · Vietnam (1) · Zambia (1)
Patrick E Duffy, M.D. (3) · Michal Fried, Ph.D. (2) · Benoit Bestgen, PhD (1) · Dr.Yeshey Dorjey (1) · Farouk Chughlay, MD (1) · Gretchen L Birbeck, MD (1) · Jacklin Mosha, MBBS, MSc, PhD (1) · Joel A Goldberg, M.D. (1) · Julie E Ledgerwood, D.O. (1) · Louis H Miller, M.D. (1) · Mariele Cristina M Picka, MSc (1) · R. Matthew Chico, MPH, PhD (1)
PMID 23929949, PMID 29692311, PMID 31584094, PMID 34194041, PMID 34379916, PMID 36316704, PMID 36708738, PMID 38640099, PMID 38857015
2019 (1), R01NS102176 (1)